<DOC>
	<DOC>NCT01205243</DOC>
	<brief_summary>An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and efficacy of ZIAGEN® administered in Korean patients according to the prescribing information.</brief_summary>
	<brief_title>ZIAGEN® Post-marketing Surveillance</brief_title>
	<detailed_description>This study will collect clinical data, mainly focused on safety, in Korean population as per the requirement of KFDA for market authorization. ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria>All subjects must satisfy the following criteria. Subject who is treated in combination with other antiretroviral agents for the treatment of HIV infection. Subject who is considered to follow this post marketing surveillance protocol by the investigator. Subject who is treated with ZIAGEN® according to the prescribing information. As considering the characteristic of observational post marketing surveillance, the exclusion criteria is not strict. All investigators should prescribe ZIAGEN® according to the prescribing information which approved in Korea. Subjects with hypersensitivity to ZIAGEN® or ingredients Subjects with moderate or severe hepatic impairment Subject with endstage renal disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Abacavir</keyword>
	<keyword>post-marketing surveillance</keyword>
</DOC>